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ABSTRACT Chronic obstructive pulmonary disease (COPD) is characterised by high morbidity and
mortality. It remains unknown which aspect of lung function carries the most prognostic information and if
simple spirometry is sufficient.
Survival was assessed in COPD outpatients whose data had been added prospectively to a clinical audit
database from the point of first full lung function testing including spirometry, lung volumes, gas transfer
and arterial blood gases. Variables univariately associated with survival were entered into a multivariate Cox
proportional hazard model.
604 patients were included (mean¡SD age 61.9¡9.7 years; forced expiratory volume in 1 s 37¡18.1%
predicted; 62.9% males); 229 (37.9%) died during a median follow-up of 83 months. Median survival was
91.9 (95% CI 80.8–103) months with survival rates at 3 and 5 years 0.83 and 0.66, respectively. Carbon
monoxide transfer factor % pred quartiles (best quartile (.51%): HR 0.33, 95% CI 0.172–0.639; and second
quartile (51–37.3%): HR 0.52, 95% CI 0.322–0.825; versus lowest quartile (,27.9%)), age (HR 1.04, 95% CI
1.02–1.06) and arterial oxygen partial pressure (HR 0.85, 95% CI 0.77–0.94) were the only parameters
independently associated with mortality.
Measurement of gas transfer provides additional prognostic information compared to spirometry in
patients under hospital follow-up and could be considered routinely.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a major public health problem. Its prevalence, morbidity
and mortality rates are increasing, and it is now the third leading cause of death worldwide [1]. However,
survival rates vary widely between studies [2, 3], possibly due to different disease coding and the inclusion
of COPD populations of varying severity. A range of pulmonary function tests is available to assess the
severity of disease in COPD, including spirometry, gas transfer measurements, plethysmographic lung
volumes and arterial blood gas analysis. The relative usefulness of these different measures remains unclear
and in the context of finite healthcare resources it is important to establish whether they provide added
value in the management of patients with this condition. In addition, where mortality is an end-point in
clinical trials, it is important to be able to select or stratify patients appropriately in order that treatment
effects can be determined accurately.
Several attempts have been made to identify potential predictors of survival among COPD patients. Since
COPD has impacts beyond the lung [4, 5], the prognostic impact of both pulmonary and extrapulmonary
factors has been investigated. Parameters of lung function and, particularly, forced expiratory volume in 1 s
(FEV1) [6, 7], age [8], sex [6, 7], body mass index (BMI) [9, 10], quadriceps strength [11], arterial blood
gases [12, 13], lung volumes [14], gas transfer [15, 16], severity of dyspnoea [17], anaemia [18, 19], presence
of comorbidities [20] and reduced physical activity or exercise capacity [21] are only some of the factors
that have been studied. However, several of these studies have been conducted in specific COPD
populations, such as selected patients with severe emphysema [2], patients using long-term oxygen
treatment (LTOT) or noninvasive mechanical ventilation [6, 22, 23], and patients during or immediately
after hospitalisation for a COPD exacerbation [7, 12, 24]. A limitation of these studies has been the
generalisability of the population and the fact that in most studies a full range of lung function measures has
not been compared [25]. Thus it has not been possible to draw definitive conclusions about the key lung
function prognostic factors in COPD.
Against this background, data from a large cohort of COPD outpatients, who had undergone
comprehensive lung function assessment and who had been prospectively entered into a clinical audit
database, were analysed to establish whether spirometry, gas transfer or lung volumes wielded the most
predictive power for survival.
Methods
Study population
Data on outpatients attending the hospital COPD clinic were entered prospectively onto a clinical audit
database. These included pulmonary function test results, anthropometrics, treatments received and
exacerbation rate. Data were extracted for individuals who had had their first full lung function testing,
including arterial blood gas analysis, performed between February 1996 and October 2010. COPD diagnosis
was clinically based on symptoms, radiology appearances and spirometry criteria, using an FEV1 to forced
vital capacity (FVC) ratio ,0.7. Patients’ treatment included inhaled b2-agonists, anticholinergics, oral
theophyllines and inhaled steroids in various combinations. Exclusion criteria were evidence of chronic
heart failure (New York Heart Association class III or IV), chronic renal failure, peripheral vascular disease
or history of malignancy. The Royal Brompton, Harefield and National Heart and Lung Institute research
ethics committee has ruled that ethical approval is not required for the retrospective analysis of routinely
collected clinical data.
Study measurements
Spirometry, gas transfer and lung volumes assessed by body plethysmography were measured using a
CompactLab System (Jaeger, Hoechberg, Germany). Quality control followed accepted guidelines, with
carbon monoxide transfer factor (TLCO) gas analyser calibrations prior to each session, volume calibrations
prior to each patient test and biological calibrations daily. Predicted values used are those of the European
Coal and Steel Community [26]. Arterial oxygen (PaO2) and carbon dioxide (PaCO2) partial pressures were
measured in arterialised earlobe capillary samples and arterio-alveolar oxygen gradient calculated.
Arterialised capillary blood sampling is carried out routinely by our clinical physiologists and is better
tolerated than an arterial puncture, while giving equivalent results [27]. For every patient, FEV1, FVC,
FEV1/FVC ratio, total lung capacity (TLC), functional residual capacity (FRC), residual volume (RV) and
inspiratory capacity (IC)/TLC ratio were recorded. The values of TLCO were adjusted for haemoglobin
concentration, according to previously published equations [28].
The annual exacerbation rate referred to the 12-month period prior to the patient’s clinic attendance and
was derived from a detailed medical history using an event-based definition; an increase in the patient’s
dyspnoea, cough and/or sputum beyond normal day-to-day variations, which required treatment with
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antibiotics and or oral corticosteroids [29]. Survival, extracted from the central National Health Service, UK
database was determined up to May 2011.
Statistical analysis
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) version 17 for
Windows XP. Data (including % predicted values) are presented as mean¡SD. Exacerbation rate was
treated a priori at the time of initial data entry as a categorical variable, separating the number of
exacerbations into three groups: 0–1, 2–4 or .4 per year. Differences between survivors and non-survivors
in demographic and clinical variables were assessed utilising the independent samples t-test or the Chi-
squared model, where appropriate. The parameters found to be univariately associated with survival were
subsequently entered in a multivariate Cox proportional hazard regression analysis model. Both FEV1 and
TLCO were entered in the survival analysis as categorical variables (Global Initiative for Chronic Obstructive
Lung Disease (GOLD) stages and TLCO quartiles, respectively), as this methodology has been previously
confirmed to better classify COPD patients with respect to survival [30, 31]. The Tukey–Hinges method was
used to calculate the TLCO quartiles. Corresponding hazard ratios and 95% confidence intervals were
calculated for each independent predictor. The median survival (with the corresponding 95% confidence
intervals) and the overall survival rates were estimated using the Kaplan–Meier method. Correlation analysis
was used to identify factors associated with PaO2. A level of p,0.05 was considered statistically significant.
Results
Study population
The study population consisted of 604 patients (380, or 62.9%, male and 224, or 37.1%, female), who had a
mean age of 62 years. According to GOLD classification, most of the patients presented with severe or very
severe disease (28.4% and 52.2%, respectively) and 17.1% of them were on LTOT. Approximately 85.5% of
the patients were treated with inhaled steroids, 82.2% with long-acting inhaled b2-agonists and 63.4% with
long acting anti-muscarinics. The demographic and clinical characteristics of the study population are
presented in table 1.
Mortality
The mean¡SD follow-up for the total population was 80¡49.8 months, while the median (95% CI) was
83.1 (6.6–210.8) months. 229 patients (37.9%) died during the follow-up period. Median (95% CI) survival
for the total population was 91.9 (80.8–103) months and survival rates at 3 and 5 years were 0.83 and 0.66,
correspondingly.
Predictors of survival
Table 2 presents the differences in patient characteristics between survivors and non-survivors. Survivors were
younger (p50.024) with less severe disease (according to GOLD classification), presented with higher BMI
(p50.004), FEV1 % pred (p,0.001), FVC % pred (p,0.001), FEV1/FVC ratio (p,0.001), TLCO % pred
(p50.015), IC/TLC % (p,0.001) and PaO2 at room air (p50.001), and a lower proportion received LTOT
(p,0.001), compared to non-survivors. Conversely, TLC % pred (p50.015), FRC % pred (p,0.001), RV %
pred (p,0.001) and PaCO2 (p50.003) were lower among the patients who were still alive at the end of the
follow-up period. The following parameters were not associated with survival differences: sex, H+
concentration, arterio-alveolar gradient, smoking status and history (pack-years), and exacerbation rate.
When these univariate predictors were entered in a proportional Cox hazard model, the parameters which
were found to predict mortality in the COPD population were age, TLCO % pred quartiles and PaO2
(table 3). When the lowest TLCO quartile (,27.9% pred) was used as reference, patients with TLCO .51%
pred and those with TLCO between 51 and 37.3% pred had significant lower mortality risk than those with
TLCO ,27.9% pred. In addition, table 4 presents these results with TLCO % pred and FEV1 % pred treated
as continuous variables. Figure 1 presents the Kaplan–Meier survival curves, adjusted for age, PaO2, GOLD
stages, FVC % pred, FEV1/FVC, TLC % pred, FRC % pred, IC/TLC, RV % pred, BMI and PaCO2 for the four
population groups, categorised by TLCO % pred quartiles. By contrast, figure 2 presents the Kaplan–Meier
survival curves, adjusted for age, PaO2, TLCO % pred quartiles, FVC % pred, FEV1/FVC, TLC % pred, FRC
% pred, IC/TLC, RV % pred, BMI and PaCO2 for the four population groups categorised by GOLD stages.
Figure E1 in the online data supplement shows receiver operating characteristic curves for survival
prediction comparing TLCO % pred, FEV1 % pred, IC/TLC and FEV1/FVC ratio. TLCO % pred had the most
predictive power with areas under the curve of 0.69, 0.67, 0.64 and 0.62 respectively.
Because oxygen therapy has an impact on survival in COPD, additional analyses were performed excluding
patients on long-term oxygen. These are available in an online data supplement (tables E1 and E2). The
results in this population were similar, with TLCO % pred again the strongest predictor of survival.
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Factors associated with PaO2
All recorded demographic and clinical parameters were investigated to identify potential determinants of
PaO2. Correlation analysis revealed positive, but weak associations between PaO2 and FEV1 %pred (r50.25,
p,0.001), TLCO % pred (r50.29, p,0.001) and IC/TLC (r50.23, p,0.001), and a moderate negative
correlation between PaO2 and PaCO2 (r5 -0.47, p,0.001). When these variables were entered in a
multivariate regression analysis model, only PaCO2 (beta5 -0.45, p,0.001) and TLCO % pred (beta50.28,
p,0.001) were retained together explaining only 26% of the variance in PaO2 values in the study population:
PaO25 -0.719 (PaCO2)+0.018 (TLCO % pred)+12.431.
Discussion
The main finding of the present study was that, in stable outpatients with COPD, TLCO % pred and PaO2, as
well as younger age, were the only variables independently associated with survival. Staging according to the
original GOLD criteria, other lung function parameters, anthropometric measures and exacerbation history
did not wield any additional prognostic information.
Significance of the findings
The present paper compares different lung function parameters directly in a group of comprehensively
assessed COPD patients. COPD is characterised by airflow obstruction due to a mixture of small airways
disease and lung parenchymal destruction [29]. FEV1 and FEV1/FVC reflect the severity of airflow
obstruction, while plethysmographic lung volumes represent the consequences of gas trapping and lung
hyperinflation due to airflow obstruction and decreased lung elastic recoil. As the product of the transfer
coefficient and alveolar volume, TLCO reflects both changes in functional lung volume and gas transport
across the alveolar–capillary membrane and thus reflects the degree of parenchymal destruction and loss of
pulmonary capillary bed, due to emphysema. In addition, the presence of processes that increase pulmonary
venous pressure, such as in left heart failure, pulmonary oedema and mitral stenosis, could also result in a
TABLE 1 Characteristics of the study population
Age years 61.9¡9.7
Sex %
Male 62.9
Female 37.1
BMI kg?m-2 24.2¡5.3
FEV1 % pred 37¡18.1
FVC % pred 84.5¡22.4
FEV1/FVC 34.7¡12.3
GOLD classification %
Stage I 2.3
Stage II 17.0
Stage III 28.4
Stage IV 52.2
TLC % pred 124.9¡18.4
RV % pred 205.1¡58.4
IC/TLC % 26.9¡8.8
FRC % pred 172.7¡38.5
TLCO % pred 40.8¡18
PaO2 kPa 9.4¡1.4
PaCO2 kPa 5.2¡0.9
Arterio-alveolar oxygen gradient kPa 5.1¡1.3
LTOT % 17.1
Current smokers % 13.2
Smoking history pack-years 43.8¡23
Exacerbations %
0–1 per year 39.1
2–4 per year 42.7
.4 per year 18.2
Data are presented as mean¡ SD, unless otherwise stated. n5604. BMI: body mass index; FEV1: forced
expiratory volume in 1 s; FVC: forced vital capacity; GOLD: Global Initiative for Obstructive Lung disease; TLC:
total lung capacity; RV: residual volume; IC: inspiratory capacity; FRC: functional residual capacity; TLCO:
carbon monoxide transfer factor; PaO2: arterial oxygen partial pressure; PaCO2: arterial carbon dioxide partial
pressure; LTOT: long-term oxygen treatment.
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reduction in TLCO [32]. These effects of both pulmonary circulation abnormalities and possibly subclinical
cardiac pathology on TLCO values could partially explain its superiority as a prognostic factor compared to
FEV1 or plethysmographic lung volumes.
To the authors’ knowledge, this is the first study identifying TLCO % pred as an independent predictor of
survival in a large, unselected general population of COPD outpatients. Although abnormal pulmonary
function has long been considered as a predictor of mortality [3, 14, 25, 33–35], most studies in COPD have
not assessed the impact of TLCO [18, 23, 36–39]. Two smaller studies have previously reported a correlation
between transfer factor and survival in stable COPD patients but only in univariate and not multivariate
analysis [15, 16]. MARTINEZ et al. [2] studied COPD patients who were randomised to the medical arm of
the National Treatment Emphysema Trial (NETT) and found no association between TLCO % pred and
survival. Although this was a larger population, it had been highly selected to meet the trial inclusion criteria
for lung volume reduction surgery eligibility. Apart from these negative results, transfer factor has been
identified as an independent predictor of survival in specific COPD subpopulations, such as patients
receiving LTOT or noninvasive mechanical ventilation [40, 41].
TABLE 2 Differences between survivors and non-survivors
Survivors Non-survivors p-value
Subjects n 375 229
Age years 61.1¡10.1 63¡9.2 0.024
Sex %
Male 62.4 63.8 NS
Female 37.6 36.2
BMI kg?m-2 24.7¡5.3 23.4¡5.2 0.004
FEV1 % pred 40.6¡18.8 30.9¡15 ,0.001
FVC % pred 88.4¡22 78.2¡21.6 ,0.001
FEV1/FVC 36.4¡12.8 31.8¡11 ,0.001
GOLD classification % ,0.001
Stage I 3.2 0.9
Stage II 22.7 7.4
Stage III 33 20.5
Stage IV 41.1 71.2
TLCO % quartiles ,0.001
Best quartile (.51) 31.3 13.9
Quartile 2 (51–37.3) 29.1 18.3
Quartile 3 (37.3–27.9) 22.2 29.3
Quartile 4 (,27.9) 17.4 38.5
TLCO % pred 44.7¡18.4 34.1¡15.2 ,0.001
TLC % pred 123.4¡17 127.5¡20.5 0.015
FRC % pred 166.1¡35.3 184.4¡41.1 ,0.001
RV % pred 195.6¡53.2 220.9¡63.1 ,0.001
IC/TLC % 28.8¡8.6 23.5¡8 ,0.001
PaO2 kPa 9.6¡1.3 9.2¡1.6 0.001
PaCO2 kPa 5.1¡0.7 5.4¡1 0.003
Arterio-alveolar oxygen gradient kPa 5¡1.3 5.1¡1.4 NS
LTOT % 11.0 27.1 ,0.001
Smoking status %
Never or ex-smokers 88.4 83.4 NS
Current smokers 11.6 16.6
Smoking history pack-years 45.6¡25.1 41.1¡19.4 NS
Exacerbations %
0–1 per year 40.3 37.1
2–4 per year 40 47.2 NS
.4 per year 19.7 15.7
Data are presented as mean¡SD, unless otherwise stated. BMI: body mass index; FEV1: forced expiratory
volume in 1 s; FVC: forced vital capacity; GOLD: Global Initiative for Obstructive Lung disease; TLCO: carbon
monoxide transfer factor; TLC: total lung capacity; FRC: functional residual capacity; RV: residual volume; IC:
inspiratory capacity; PaO2: arterial oxygen partial pressure; PaCO2: arterial carbon dioxide partial pressure;
LTOT: long-term oxygen treatment; NS: nonsignificant.
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Arterial oxygen partial pressure breathing room air was also a strong predictor of survival in this cohort.
This is consistent with the findings of several previous studies, in which PaO2 values were positively
associated with survival, both in COPD patients who were on LTOT [18, 23, 42] and those who were not
[42]. Although some authors have failed to identify such an association in the past [8, 22], most of the latter
studies were conducted in smaller, often non-general COPD populations and PaO2 was sometimes measured
on supplementary oxygen, which could explain discrepant findings. In the present dataset, only 26% of the
variance in PaO2 was explained by other lung function parameters. This supports the concept that PaO2
reflects an integration of factors, including ventilation perfusion mismatch and cardiac output, neither of
TABLE 3 Predictors of mortality in the total chronic obstructive pulmonary disease population,
according to the multivariate Cox regression analysis
HR (95% CI) p-value
Age years 1.034 (1.009–1.059) 0.007
PaO2 kPa 0.860 (0.755–0.979) 0.023
TLCO % pred 0.006
Best quartile (.51) 0.332 (0.172–0.639) 0.001
Quartile 2 (51–37.3) 0.515 (0.322–0.825) 0.006
Quartile 3 (37.3–27.9) 0.711 (0.477–1.059) 0.093
Quartile 4 (,27.9) Reference
GOLD classification 0.125
Stage I 0.506 (0.087–2.94) 0.448
Stage II 0.407 (0.176–0.939) 0.035
Stage III 0.639 (0.408–1.002) 0.053
Stage IV Reference
FVC % pred 0.989 (0.969–1.010) 0.250
FEV1/FVC 1.015 (0.994–1.037) 0.170
RV % pred 0.988 (0.975–1.051) 0.079
FRC % pred 1.023 (0.999–1.048) 0.057
TLC % pred 1.008 (0.976–1.041) 0.633
IC/TLC % 2.15 (0.37–3.293) 0.418
PaCO2 kPa 0.985 (0.796–1.218) 0.887
BMI kg?m-2 1.009 (0.970–1.036) 0.903
PaO2: arterial oxygen partial pressure; TLCO; carbon monoxide transfer factor; GOLD: Global Initiative for
Obstructive Lung disease; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; RV: residual
volume; FRC: functional residual capacity; TLC: total lung capacity; IC: inspiratory capacity; PaCO2: arterial
carbon dioxide partial pressure; BMI: body mass index.
TABLE 4 Predictors of mortality in the total chronic obstructive pulmonary disease population,
according to the multivariate Cox regression analysis
HR (95% CI) p-value
Age years 1.030 (1.004–1.056) 0.021
PaO2 kPa 0.851 (0.748–0.969) 0.015
TLCO % pred 0.971 (0.957–0.984) ,0.001
FEV1 % pred 1.016 (0.974–1.060) 0.463
FVC % pred 0.977 (0.950–1.004) 0.090
FEV1/FVC 0.988 (0.944–1.033) 0.582
RV % pred 0.987 (0.975–1.001) 0.055
FRC % pred 1.021 (0.998–1.045) 0.078
TLC % pred 1.011 (0.979–1.044) 0.507
IC/TLC % 2.009 (0.378–3.451) 0.628
PaCO2 kPa 0.991 (0.798–1.230) 0.932
BMI kg?m-2 1.006 (0.973–1.041) 0.710
Carbon monoxide transfer factor (TLCO) % pred and forced expiratory volume in 1 s (FEV1) % pred entered the
analysis as continuous variables. PaO2: arterial oxygen partial pressure; FVC: forced vital capacity; RV: residual
volume; FRC: functional residual capacity; TLC: total lung capacity; IC: inspiratory capacity; PaCO2: arterial
carbon dioxide partial pressure; BMI: body mass index.
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which are well captured by conventional lung function measurements (airflow, lung volumes and gas
transfer) but which may have implications for survival since cardiovascular morbidity and mortality is
common in COPD [5].
Several parameters were not independently associated with survival in the current study. FEV1 was higher
among survivors, but this difference was significant only in the univariate analysis, indicating that TLCO is a
better prognostic indicator. Although there are previous studies where FEV1 was identified as a predictor of
survival in COPD [3, 6, 43], several others have had findings similar to ours, since they failed to find such an
association [9, 12, 24]. Furthermore, a recent review concluded that FEV1 can probably predict mortality
better as a component of the BODE (BMI, airflow obstruction, dyspnoea and exercise tolerance) index, than
as an individual parameter [33]. CASANOVA et al. [14] identified the IC/TLC ratio (or ‘‘inspiratory fraction’’)
as a predictor of mortality in a study which included a large number of COPD outpatients; however, TLCO
was not measured in that cohort. In the only study in which the prognostic value of IC/TLC was assessed in
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FIGURE 1 The Kaplan–Meier survival curves, adjusted for age, arterial oxygen partial pressure, Global Initiative for
Chronic Obstructive Lung Disease classification, forced vital capacity (FVC) % pred, forced expiratory volume in 1 s to
FVC ratio, total lung capacity (TLC) % pred, functional residual capacity % pred, inspiratory capacity to TLC ratio,
residual volume % pred, body mass index and arterial carbon dioxide partial pressure for the four population groups,
categorised by carbon monoxide transfer factor (TLCO) % pred quartiles.
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FIGURE 2 The Kaplan–Meier survival curves, adjusted for age, arterial oxygen partial pressure, carbon monoxide transfer
factor % pred quartiles, forced vital capacity (FVC) % pred, forced expiratory volume in 1 s to FVC ratio, total lung
capacity (TLC) % pred, functional residual capacity % pred, inspiratory capacity to TLC ratio, residual volume % pred,
body mass index and arterial carbon dioxide partial pressure for the four population groups, categorised by Global
Initiative for Chronic Obstructive Lung Disease (GOLD) stages. Survival only differed significantly between GOLD stage
II and IV (p50.04).
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combination with transfer factor, TLCO and not the inspiratory fraction was identified as an independent
predictor of mortality [44], a finding which is confirmed by our results.
As in previous studies, older age was a predictor of reduced survival [11]. With a few exceptions [15, 22],
this has been a consistent finding among both general COPD populations and COPD patients receiving
LTOT [2, 17, 33, 40], though recently, of COPD phenotypes identified by cluster analysis, the one with the
worst survival was younger patients with severe airflow limitation, a low BMI, frequent exacerbations and
low rates of cardiovascular morbidities [45]. However, the most important finding regarding age in this
study is that it can predict survival independently from the stage of the disease judged by the severity of
airflow obstruction.
The present findings in COPD patients can also be considered in the light of data available from the general
population suggesting that vital capacity rather than airflow obstruction is associated with mortality [46]. In
a large population of people undergoing lung function for a wide range of indications, TLCO was the most
powerful predictor of survival [47]. This study also observed some variation in the predictive power of lung
function parameters depending on the equation used to generate predicted values, though it is unlikely that
this would have significantly altered the present findings.
Methodological issues
The study was based on prospectively collected comprehensive clinical data from patients under hospital
care for management of their COPD. Other studies in this area have tended to measure only a limited
selection of lung function tests (e.g. in the ECLIPSE trial gas transfer was not measured) [25, 35], to have
had highly selected populations (e.g. the ‘‘medical’’ arm of the NETT trial) [2], or to include small cohorts
only [11, 44]. The single centre approach has minimised bias regarding different patient populations and
various measurement techniques that might have occurred in multicentre cohorts. Usual clinical practice
was for patients to undergo routine comprehensive lung function assessment, including blood gas analysis,
so it is unlikely that the results are biased by any specific indication for lung function testing.
The use of the UK National Health Service central data spine allowed us to establish the vital status of all
participants. Data on cause of death were not available which might have allowed us to refine causal
hypotheses linking lung function to mortality. As described above, an issue in previous studies of factors
associated with survival in COPD has been one of the generalisability of the population. We studied a
hospital clinic population likely to have a predominance of emphysema. This might have influenced the
association between gas transfer measurements and survival, since there is an established correlation
between emphysema severity and TLCO. Some caution is needed in extrapolating outcomes to patients with
milder disease, but the findings are likely to be applicable to secondary care patients in general.
We chose to define exacerbations as episodes of worsening of disease sufficient to cause patients to seek
medical assistance and receive a prescription for antibiotics. This definition can, to some extent, be
criticised as dependent on behaviour but has the merit of incorporating an element of ‘‘clinical
significance’’. Techniques such as diary cards have been developed and this remains an area of controversy
[48] but, to date, no consensus exists in the literature as to which is the ‘‘gold standard’’. It seems unlikely
that a different definition would have caused any systematic difference in the results obtained.
Patients were diagnosed with COPD on clinical grounds, including an FEV1/FVC ratio of ,0.7. The lower
limit of normal for this ratio is now considered to be a more reliable threshold for diagnosing airflow
obstruction. However, since the fixed ratio was the one that was used when patients were being diagnosed
initially and entered onto the COPD database it would be inappropriate to change this retrospectively. In
addition, the relatively small number of patients with mild airflow obstruction, where the risk of
misclassification is highest, makes this unlikely to jeopardise the findings of the study.
The present study compares the prognostic power of different lung function tests in predicting mortality.
The Medical Research Council dyspnoea score was not recorded systematically so it is not possible to
calculate the ADO (age, dyspnoea and obstruction) score or BODE score (the latter also requires a walking
distance to be measured) and direct comparison is not possible [49].
In conclusion, in a large, general COPD outpatient population where a complete range of lung function
testing had been applied, gas transfer provided the best prediction of survival, together with age and PaO2.
Spirometry, although easy to perform and low-cost, cannot offer as much information as gas transfer, which is
also superior to plethysmographic lung volume measurements. An argument can therefore be made for
performing measures of gas transfer in routine practice for patients with COPD to provide them with the best
prognostic information, and future classifications of COPD should include TLCO and not rely merely on the
severity of airflow obstruction. The results may also inform trial design, suggesting that gas transfer should
also be used for stratification where therapies that are intended to influence mortality are to be tested.
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